We applied partitioning analysis by using the 3-year DFS rate as the response endpoint and patient age (<65 vs ≥65), tumour stage (stage II vs stage III), tumour site (Right vs Left CRC), KRAS mutational status (wild-type vs any exon 2, 3, 4 mutation) and tumour mIS (tumour CD3/CD8 mRNA cluster-low vs cluster-high) as input factors in the 267 patients who had all the above data available. The gene discussed is CD8A; the disease is neoplasm.